Drug Profile
Research programme: Janus kinase inhibitors - BioCryst
Latest Information Update: 11 Dec 2012
Price :
$50
*
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer